C12N 2502/99
Genetically modified cells
Official title: genetically modified cells
C12N2502/99 (Genetically modified cells) appears on 225 US grants and 434 published applications in this corpus.
Search patents in C12N- Granted patents
- 225
- Published applications
- 434
- Assignees
- 205
- Inventors
- 678
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 4 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 12 |
| 2003 | 6 | 20 |
| 2004 | 2 | 16 |
| 2005 | 2 | 15 |
| 2006 | 3 | 8 |
| 2007 | 4 | 4 |
| 2008 | 4 | 8 |
| 2009 | 7 | 14 |
| 2010 | 9 | 8 |
| 2011 | 9 | 21 |
| 2012 | 13 | 14 |
| 2013 | 5 | 9 |
| 2014 | 10 | 21 |
| 2015 | 10 | 6 |
| 2016 | 5 | 15 |
| 2017 | 11 | 19 |
| 2018 | 8 | 15 |
| 2019 | 13 | 22 |
| 2020 | 8 | 23 |
| 2021 | 13 | 32 |
| 2022 | 19 | 40 |
| 2023 | 8 | 21 |
| 2024 | 14 | 36 |
| 2025 | 15 | 21 |
| 2026 | 9 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Methods for reducing elevated glucose levels11 Aug 2026US 12,703,856 B2SDF BioPharma Inc.
- Methods for engineering allogeneic and highly active T cell for immunotheraphy14 Jul 2026US 12,680,076 B2Cellectis
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production16 Jun 2026US 12,655,391 B2Gene Solutions Joint Stock Company
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion17 Sep 2026US 2026/0274920 A1Iovance Biotherapeutics, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275285 A1Iovance Biotherapeutics, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275286 A1Iovance Biotherapeutics, Inc.
- A synthetic cellular advanced signal adapter (scasa) system20 Aug 2026US 2026/0242721 A1Danmarks Tekniske Universitet
- Methods of targeting glycogen synthase kinase 3 beta in nk cells6 Aug 2026US 2026/0226413 A1Research Institute At Nationwide Children's Hospital
Most cited
By later US patents
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells210US 5,437,994 AThe Regents of the University of Michigan · 1995
- Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells151US 5,763,266 AThe Regents of the University of Michigan · 1998
- Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture146US 5,635,386 AThe Regents of the University of Michigan · 1997
- Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells145US 5,646,043 AThe Regents of the University of Michigan · 1997